Company Description
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.
BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania.
The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.
BioRestorative Therapies, Inc. is based in Melville, New York.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Lance Alstodt |
Contact Details
Address: 40 Marcus Drive Melville, New York 11747 United States | |
| Phone | (631) 760-8100 |
| Website | biorestorative.com |
Stock Details
| Ticker Symbol | BRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505497 |
| CUSIP Number | 090655606 |
| ISIN Number | US0906556065 |
| Employer ID | 30-1341024 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Lance Alstodt | Chairman of the Board, President and Chief Executive Officer |
| Robert Eugene Kristal | Chief Financial Officer |
| Francisco J. Silva | Chief Scientist, Vice President of Research and Development, Secretary and Director |
| Robert Paccasassi | Vice President of Quality Assurance and Regulatory Compliance |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc and Spine Program and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | SCHEDULE 13G | Filing |
| Jun 11, 2024 | 10-Q | Quarterly Report |
| Jun 11, 2024 | 10-K/A | [Amend] Annual report |
| May 24, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 16, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 19, 2024 | 424B3 | Prospectus |
| Apr 18, 2024 | EFFECT | Notice of Effectiveness |
| Apr 12, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 11, 2024 | UPLOAD | Filing |